TOP TEN perturbations for NM_000223 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000223
Selected probe(set): 207811_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000223 (207811_at) across 5339 perturbations tested by GENEVESTIGATOR:

ulcerative colitis study 9 (prior therapy) / normal colon tissue

Relative Expression (log2-ratio):-2.041543
Number of Samples:8 / 11
Experimental ulcerative colitis study 9 (prior therapy)
Colon biopsies derived from pediatric patients diagnosed with ulcerative colitis at time of enrollment. Patients were not receiving medications for the treatment of inflammatory bowel disease at the time the biopsy was taken.
Control normal colon tissue
Colon biopsies derived from pediatric healthy controls.

valproic acid study 26 (2000uM) / vehicle (PBS) treated HepG2 sample

Relative Expression (log2-ratio):2.004683
Number of Samples:3 / 12
Experimental valproic acid study 26 (2000uM)
HepG2 cells treated with compound: valproic acid (2000uM; CAS no.:99-66-1) for 24 hours. Valproic acid is hepatotoxic and may cause steatosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:
Control vehicle (PBS) treated HepG2 sample
HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-1.6451359
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

Crohn's disease study 6 (colon only; prior therapy) / normal colon tissue

Relative Expression (log2-ratio):-1.4716778
Number of Samples:5 / 11
Experimental Crohn's disease study 6 (colon only; prior therapy)
Colon biopsies derived from pediatric patients diagnosed with colon-only Crohn's disease (any colonic location between cecum and rectum with no small bowel disease) at time of enrollment. Patients were not receiving medications for the treatment of inflammatory bowel disease at the time the biopsy was taken. Patients may also have concomitant upper gastrointestinal tract and/or perianal disease.
Control normal colon tissue
Colon biopsies derived from pediatric healthy controls.

PMA study 7 (24h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):1.4277859
Number of Samples:3 / 7
Experimental PMA study 7 (24h)
HepG2 cells exposed to 500nM phorbol-12-myristat-13-acetate [(PMA ortetradecanoyl phorbol acetate (TPA)] in DMSO solvent for 24 hours. ATC code:---
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 24 hours.

PMA study 8 (0.0001 uM; Hep-G2) / vehicle (DMSO) treated Hep-G2 cell sample

Relative Expression (log2-ratio):1.4108391
Number of Samples:3 / 9
Experimental PMA study 8 (0.0001 uM; Hep-G2)
Hep-G2 cells exposed to 0.0001 uM PMA (dissolved in 0.5% v/v DMSO) for 72 hours. Synonyms: phorbol-12-myristat-13-acetate (PMA), tetradecanoylphorbol-acetate (TPA), tetradecanoyl phorbol acetate, 12-O-tetradecanoylphorbol-13-acetate. Cells were exposed to the chemical when 80% confluence was reached. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated Hep-G2 cell sample
Hep-G2 cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Cells were exposed to the vehicle when 80% confluence was reached.

Crohn's disease study 6 (colon only; under therapy) / normal colon tissue

Relative Expression (log2-ratio):-1.3932257
Number of Samples:4 / 11
Experimental Crohn's disease study 6 (colon only; under therapy)
Colon biopsies derived from pediatric patients diagnosed with colon-only Crohn's disease (any colonic location between cecum and rectum with no small bowel disease) enrolled during therapy. Patients were receiving medications for the treatment of inflammatory bowel disease at the time the biopsy was taken. Patients may also have concomitant upper gastrointestinal tract and/or perianal disease.
Control normal colon tissue
Colon biopsies derived from pediatric healthy controls.

Crohn's disease study 3 (baseline; non-responder; colon) / normal colon mucosa tissue

Relative Expression (log2-ratio):-1.257762
Number of Samples:7 / 6
Experimental Crohn's disease study 3 (baseline; non-responder; colon)
Colonic mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):-1.2019367
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):-1.1980944
Number of Samples:16 / 6
Experimental ulcerative colitis study 5 (baseline; non-responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.